Platform leverages muscle biology to de-risk development and identify new therapeutic targets ahead of clinical entry ...

PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect ...

Jesy Nelson’s twins were diagnosed with spinal muscular atrophy (SMA) too late but now the NHS will start testing babies at ...

The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle ...

THE father of a boy with a severe muscle wasting condition said waiting more than a year for regulatory approval of a drug to ...

The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.

Patients with rheumatoid arthritis increased their leg muscle volume when treated with an anti-rheumatic drug, offering new hope for improved muscle health. Publishing in the prestigious journal, The ...

Research intended to help people with muscle-wasting diseases could be about to launch a new era in performance-enhancing drugs. The research has produced several muscle-building drugs now being ...

Spinal and Bulbar Muscular Atrophy (SBMA) is a rare inherited disease that causes progressive muscle weakness and wasting in ...